Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease
Source abstract
Abstract
S100 coated pellets. The in vivo evaluation of developed system was performed by employing oxazolone colitis rat model. The average particle size of Mn-NLCs (301.7 ± 2.88 nm) was found to be more than that of unconjugated NLCs (284.0 ± 4.53 nm) with marginally reduced % entrapment efficiency (90.88 ± 3.86%). The in vitro cytotoxicity studies using J774A.1 cell line revealed that Mn-NLCs were non-toxic as compared to pure drug. The in vivo evaluation depicted that Mn-NLCs showed significant reduction in clinical activity scoring, macroscopic and microscopic indexing, colonic myeloperoxidase activity and inflammatory cytokines. In conclusion, the developed Mn-NLCs appear to be promising for the treatment of IBD by selectively targeting inflamed colonic region as compared to unconjugated nanoparticulate system.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inflammatory Bowel Disease · Nanoparticle-Based Drug Delivery · Microscopic Colitis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India;
Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Funding
Department of Science and Technology
References (51)
Show source-provided references
1. 10.1016/j.ejpb.2008.12.01310.1016/j.ejpb.2008.12.013 ↗
2. 10.1211/002235705617210.1211/0022357056172 ↗
3. 10.1211/002235701177665810.1211/0022357011776658 ↗
4. 10.1124/jpet.105.08814610.1124/jpet.105.088146 ↗
5. 10.2174/156801003348418810.2174/1568010033484188 ↗
6. 10.1615/CritRevTherDrugCarrierSyst.v24.i2.2010.1615/CritRevTherDrugCarrierSyst.v24.i2.20 ↗
7. 10.1615/CritRevTherDrugCarrierSyst.v28.i6.1010.1615/CritRevTherDrugCarrierSyst.v28.i6.10 ↗
8. 10.1517/17425247.2011.59773910.1517/17425247.2011.597739 ↗
9. 10.1517/17425247.2013.78228410.1517/17425247.2013.782284 ↗
10. 10.1517/17425247.2014.92744010.1517/17425247.2014.927440 ↗
11. 10.1517/17425247.2015.106021710.1517/17425247.2015.1060217 ↗
12. 10.1517/17425247.2016.116620310.1517/17425247.2016.1166203 ↗
13. Youshia J · Expert Opin Drug Deliv · 2015 · 4 · 1
14. 10.1016/j.jconrel.2014.05.04610.1016/j.jconrel.2014.05.046 ↗
15. 10.1016/j.biomaterials.2013.06.00810.1016/j.biomaterials.2013.06.008 ↗
16. 10.1073/pnas.83.8.250110.1073/pnas.83.8.2501 ↗
17. 10.1080/03639045.2018.143419410.1080/03639045.2018.1434194 ↗
18. 10.1080/1061186060082515910.1080/10611860600825159 ↗
19. 10.1016/j.jconrel.2010.09.00310.1016/j.jconrel.2010.09.003 ↗
20. 10.1016/j.carbpol.2011.04.06810.1016/j.carbpol.2011.04.068 ↗
21. 10.3109/10717544.2010.53844710.3109/10717544.2010.538447 ↗
22. 10.1002/jps.2240610.1002/jps.22406 ↗
23. 10.3109/10837450.2011.65381910.3109/10837450.2011.653819 ↗
24. Patel MM · Acta Pharm Sci · 2009 · 51 · 251
25. 10.1080/1083745080240941210.1080/10837450802409412 ↗
26. 10.1007/s13346-017-0358-710.1007/s13346-017-0358-7 ↗
27. Lamprecht A · J Pharmacol Exp Ther · 2001 · 299 · 77510.1016/S0022-3565(24)29290-9 ↗
28. 10.1016/j.ijpharm.2013.05.01710.1016/j.ijpharm.2013.05.017 ↗
29. 10.1136/gut.47.3.40410.1136/gut.47.3.404 ↗
30. 10.1038/sj.bjp.070471910.1038/sj.bjp.0704719 ↗
31. 10.1152/ajpgi.2000.278.3.G46710.1152/ajpgi.2000.278.3.G467 ↗
32. 10.1038/257393a010.1038/257393a0 ↗
33. 10.1084/jem.188.10.192910.1084/jem.188.10.1929 ↗
34. Panaccione R. · Gastroenterol Hepatol (N Y) · 2013 · 9 · 529
35. 10.1136/gut.2003.03575810.1136/gut.2003.035758 ↗
36. 10.3390/ijms13081011310.3390/ijms130810113 ↗
37. 10.1016/j.addr.2013.05.00710.1016/j.addr.2013.05.007 ↗
38. 10.1080/0036552985016691410.1080/00365529850166914 ↗
39. 10.3109/10715762.2012.73269810.3109/10715762.2012.732698 ↗
40. 10.1111/j.1440-1746.2005.03862.x10.1111/j.1440-1746.2005.03862.x ↗
41. 10.1056/NEJMra02083110.1056/NEJMra020831 ↗
42. 10.1016/S0399-8320(09)73151-310.1016/S0399-8320(09)73151-3 ↗
43. 10.1111/apt.1337510.1111/apt.13375 ↗
44. 10.3748/wjg.v9.i12.263510.3748/wjg.v9.i12.2635 ↗
45. 10.1038/cmi.2012.110.1038/cmi.2012.1 ↗
46. 10.1002/ibd.2292910.1002/ibd.22929 ↗
47. Dadwal NA · Artif Cells Nanomed Biotechnol · 2017 · 45 · 110.3109/21691401.2016.1153483 ↗
48. 10.3109/21691401.2015.112961710.3109/21691401.2015.1129617 ↗
49. 10.1080/21691401.2017.142349710.1080/21691401.2017.1423497 ↗
50. 10.1080/21691401.2016.119836310.1080/21691401.2016.1198363 ↗
51. 10.3109/21691401.2014.90982210.3109/21691401.2014.909822 ↗